What's Next in CNS Drug Discovery? Five Studies Worth Exploring
At Transpharmation, we’re focused on generating the translational data our clients need to make smarter, more confident development decisions. This month, we’re highlighting new research across:
- Alzheimer's disease
- Depression research
- Alcohol use disorder
- Emerging CNS therapeutics
- Impulsivity
Whether you’re advancing a novel CNS therapeutic or de-risking an existing program, these examples demonstrate how translational models and objective endpoints can help support critical R&D decisions.
What Can Sleep and EEG Changes Reveal About Alzheimer’s Disease Progression?
Longitudinal Characterization of Sleep and EEG in the ARTE10 Mouse Model
Understanding how sleep and brain activity change during Alzheimer’s disease progression may provide valuable insights for evaluating potential therapeutics.
Key finding: Transpharmation's longitudinal research using the ARTE10 mouse model of Alzheimer's disease reveals progressive alterations in sleep architecture, EEG activity, and network excitability across disease development.
Sleep-EEG in the ARTE10 model: sleep-spindle activity in wild-type vs. ARTE10 heterozygous mice.
These findings highlight the potential of sleep and EEG phenotypes to strengthen the translational utility of the ARTE10 model, supporting the evaluation of future therapeutics targeting Alzheimer’s disease and its associated comorbidities.
Explore our Alzheimer’s disease research to see how the ARTE10 model and sleep-EEG can support your next study:
Explore Alzheimer's research →or see our EEG capabilities · talk to our scientific team
Could Metabolic Therapeutics Offer New Directions for Depression Research?
GLP-1R Agonist and Dual GIPR/GLP-1R Agonism Show Antidepressant-Like Activity in a Translational Mouse Model of Depression
Could therapeutic approaches traditionally associated with metabolic diseases offer new possibilities for depression research?
Key finding: Transpharmation's preclinical research demonstrates antidepressant-like activity associated with both GLP-1 receptor agonism and dual GIPR/GLP-1R agonism in a translational mouse model of depression.
These findings raise important questions about the role of incretin signaling in neuropsychiatric disease and highlight the potential for exploring novel therapeutic approaches beyond traditional antidepressants.
Want the full GLP-1 dataset? Reply to this email or send us a request, and we’ll send you our latest poster as soon as it’s released. Request the poster →
or see our metabolic disorders research · talk to our scientific team
Could 5-MeO-DMT Offer a New Direction for Alcohol Use Disorder Research?
5-MeO-DMT Selectively Attenuates Oral Ethanol Self-Administration in Male and Female Wistar Rats
Exploring novel therapeutic approaches for alcohol use disorder requires understanding how potential compounds influence alcohol-related behaviors.
Key finding: Transpharmation's preclinical research demonstrates that 5-MeO-DMT selectively reduced oral ethanol self-administration in both male and female Wistar rats, with effects that differed from those observed with a current standard-of-care comparator.
These findings highlight the potential relevance of 5-MeO-DMT in alcohol use disorder research and raise important questions about its possible role in the development of novel therapeutics.
Explore our abuse liability and substance use disorder research to see how these models can support your next study:
Explore substance use research →or see our psychedelics research · talk to our scientific team
Can 5-HT2A Receptor Activation Be Separated from Psychedelic-Like Effects?
Application of Drug Discrimination Techniques to the Characterization of Novel Non-Psychedelic 5-HT2A Receptor Agonists
As interest in neuroplasticity-promoting therapeutics continues to grow, an important question remains: can the therapeutic potential associated with 5-HT2A receptor activation be separated from psychedelic-like activity?
Key finding: Transpharmation's preclinical research applies translational drug discrimination techniques to evaluate novel non-psychedelic 5-HT2A receptor agonists, exploring approaches to characterize compounds targeting central nervous system (CNS) disorders.
This research highlights the potential value of drug discrimination techniques in characterizing novel compounds and supporting the development of therapeutic approaches targeting CNS disorders.
Explore our psychedelics research to see how drug discrimination can help characterize your compounds:
Explore psychedelics research →or see our operant platform · talk to our scientific team
From ADHD to OCD: Can Impulsivity Be Measured as a Translational Endpoint?
Pharmacological and Phenotypic Validation of the Differential Reinforcement of Low Rates Task for Assessing Impulsive Action in Mice
Understanding and assessing impulsive action is an important consideration in research involving disorders where impulsivity plays a central role.
Transpharmation's preclinical research focuses on the pharmacological and phenotypic validation of the Differential Reinforcement of Low Rates (DRL) task, investigating its utility for assessing impulsive action in mice.
This research explores how the DRL model responds to pharmacological validation and highlights its potential value in studying impulsivity-related disorders, supporting the characterization of behavioral responses relevant to therapeutic research.
Explore our operant platform to see how DRL and related assays can support your impulsivity research:
Explore our operant platform →or see our posters and publications · talk to our scientific team
- the best validated assays to identify drugs for the quickest time to market
- specialized laboratories with custom capabilities to suit your needs
Meet with us at Neuroscience 2026
Want to learn more about the research in this edition? Transpharmation is heading to SfN 2026 in Washington, DC, November 14–18, with our largest-ever scientific presence at the meeting. Our team will be presenting all five of these studies and would welcome the opportunity to discuss your neuroscience, neuropsychiatric, or abuse liability programs.
SfN Neuroscience 2026 · Visit us at Booth #717
Washington, DC, USA · November 14 – 18
Scientific posters · Sunday, November 15, 1:00 – 5:00 PM
- Longitudinal Characterization of Sleep and EEG in the ARTE10 Mouse Model · Daniel Hutcheson, PhD
- GLP-1R Agonist and Dual GIPR/GLP-1R Agonism Show Antidepressant-Like Activity in a Translational Mouse Model of Depression · Ewa Sokołowska, PhD
- Application of Drug Discrimination Techniques to the Characterization of Novel Non-Psychedelic 5-HT2A Receptor Agonists · Guy Higgins, PhD
Scientific posters · Wednesday, November 18, 1:00 – 5:00 PM
- 5-MeO-DMT Selectively Attenuates Oral Ethanol Self-Administration in Male and Female Wistar Rats · Briana Renda, PhD
- Pharmacological and Phenotypic Validation of the Differential Reinforcement of Low Rates Task for Assessing Impulsive Action in Mice · Guy Higgins, PhD
We still have a few meeting slots available!
Book a meeting at SfNBe the first to know. Get InPharmation straight to your inbox.
Sign up to receive the latest scientific advancements by email.